DJIA 17,612.29 -71.29 -0.40%
NASDAQ 4,945.85 -46.10 -0.92%
S&P 500 2,062.97 -5.79 -0.28%
market minute promo

Seattle Genetics (NASDAQ: SGEN)

46.88 -0.62 (-1.31%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

SGEN $46.88 -1.31%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.59
Previous Close $47.50
Daily Range $46.14 - $47.98
52-Week Range $30.05 - $49.84
Market Cap $5.9B
P/E Ratio -71.97
Dividend (Yield) $0.00 (0.0%)
Volume 352,073
Average Daily Volume 858,204
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drug Makers

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

News & Commentary

Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?

Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.

How To Make Money In Small To Nano-Cap Biotech

Interesting SGEN Put And Call Options For August 21st

Seattle Genetics' Collaborative Approach To Fighting Cancer Makes It A Buy

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the Intern

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutic

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases

Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog

3 Stocks Improving Performance Of The Drugs Industry

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

Seattle Genetics Larger Than S&P 500 Component Tenet Healthcare

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Program

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs

See More SGEN News...

SGEN's Top Competitors

SGEN $46.88 (-1.31%)
Current stock: SGEN
AMGN $154.36 (-0.09%)
Current stock: AMGN
GILD $114.46 (-1.04%)
Current stock: GILD
BIIB $405.90 (0.31%)
Current stock: BIIB